This is one hell of a hit piece. I'd love to see the actual quote from the CEO since this has gotten ZERO press in the mainstream media. I'm assuming he meant the drug was priced for westerns who could afford it, not that the company would prefer if Indians with cancer would just die.
The thing that makes me laugh about the IP struggle going on in India is that Indian companies who have developed their own generic versions have often priced their drugs not much lower than what western companies have[1]. This isn't about providing access to medicines (since many western companies, including Bayer, have patient assistance programs that offer free drug to Indians), this is about protecting and supporting the Indian pharmaceutical manufacturers.
[1] Biocon just launched their biosimilar version of Genentech's Herceptin. Genentech's price in India is $1,366 per month while Biocon's is $933 per month, still well out of the reach of most Indians.
The thing that makes me laugh about the IP struggle going on in India is that Indian companies who have developed their own generic versions have often priced their drugs not much lower than what western companies have[1]. This isn't about providing access to medicines (since many western companies, including Bayer, have patient assistance programs that offer free drug to Indians), this is about protecting and supporting the Indian pharmaceutical manufacturers.
[1] Biocon just launched their biosimilar version of Genentech's Herceptin. Genentech's price in India is $1,366 per month while Biocon's is $933 per month, still well out of the reach of most Indians.
http://www.bloomberg.com/news/2014-01-20/roche-herceptin-cop...